MedPAC Meets to Discuss Biosimilars

On October 6-7, 2016, the Medicare Payment Advisory Commission (MedPAC), a federal agency that advises Congress on Medicare pay policies, held a public meeting, with one session titled “Biosimilars in Medicare Part D.”  This session concerned, among other things, market acceptance of biosimilars, including issues relating to interchangeability and costs.  An earlier session titled “Medicare Part B drug payment policy issues,” also discussed, among other things, consolidated billing codes for reference biologics and biosimilars.  The transcript associated with this session can be found here.